Publications by authors named "E Luporsi"
Article Synopsis
- Cancer-treatment toxicity is common, and quick identification of symptoms is vital; to improve symptom reporting, a mobile ePROM app called QuestOnco was developed for real-time monitoring and reporting of cancer-treatment symptoms.
- The application was designed with patient comprehension in mind and was validated through a cohort study that included 24 cancer patients in Stage I, who had no comprehension issues, and 110 patients in Stage II who used QuestOnco alongside traditional reporting methods.
- Results showed high engagement with QuestOnco, indicating its potential for enhancing real-time symptom reporting and improving alignment with other reporting tools like PRO-CTCAE and medical records.
Article Synopsis
- Breast cancer is the most prevalent cancer among women globally, and research indicates that larger tumors increase the risk of metastatic disease, prompting an evaluation of breast self-examination (BSE) versus breast awareness.
- The Commission of Senology (CS) of CNGOF utilized established assessment methods to determine the effectiveness of BSE across different groups of women, including general and high-risk populations.
- The findings suggest BSE is not recommended for the general female population, who are encouraged to rely on clinical exams and screenings, while no clear guidelines were established for women over 75 or those with a history of breast cancer due to insufficient data on BSE's benefits for these groups.
[News in breast oncology genetics for female and male population].
Gynecol Obstet Fertil Senol
March 2024
Objectives: Breast oncology genetics emerged almost 30 years ago with the discovery of the BRCA1 and BRCA2 genes. The evolution of analytical practices has progressively allowed access to tests whose results now have a considerable impact on the management of both female and male breast cancers. The Sénologie commission of the Collège national des gynécologues et obstétriciens français (CNGOF) asked five specialists in breast surgery, oncology and oncological genetics to draw up a summary of the oncogenetic testing criteria used and the clinical implications for the female and male population of the test results, with or without an identified causal variant.
View Article and Find Full Text PDFObjectives: Breast cancer is the most common female cancer in the world. In France, over 60,000 new cases are currently diagnosed, and 12,000 deaths are attributed to it annually. Numerous studies have shown that the risk of metastatic disease increases with tumor volume.
View Article and Find Full Text PDFBackground: Three partially overlapping breast cancer polygenic risk scores (PRS) comprising 77, 179 and 313 SNPs have been proposed for European-ancestry women by the Breast Cancer Association Consortium (BCAC) for improving risk prediction in the general population. However, the effect of these SNPs may vary from one country to another and within a country because of other factors.
Objective: To assess their associated risk and predictive performance in French women from (1) the CECILE population-based case-control study, (2) BRCA1 or BRCA2 (BRCA1/2) pathogenic variant (PV) carriers from the GEMO study, and (3) familial breast cancer cases with no BRCA1/2 PV and unrelated controls from the GENESIS study.